The global lopinavir/ritonavir market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The combination of lopinavir and ritonavir is used with other drugs to treat human immunodeficiency HIV infection and other types of cancer. The rising prevalence of the HIV along with the development of advanced treatment options is a key factor driving the growth of the global lopinavir/ritonavir market. According to the World Health Organization (WHO), in 2019 there were approximately 38 million people worldwide living with HIV. Moreover, 36.2 million were adults and 1.8 million were children below 15 years old.
The cohesive government policies is further contributing to the market growth. For instance, in 2020 after the Israeli government approved the licensing of the common Kaletra HIV anti-coronavirus pill, AbbVie Inc. agreed to allow the country to purchase copycat versions of its drug from foreign suppliers, a rare occurrence in which the threat of compulsory licensing drug additive access. In addition, the growing focus of pharmaceutical companies on additional treatment options, and increased awareness are factors that will increase the global market for lopinavir/ritonavir.
According to NCBI research, the lopinavir/ritonavir is the first and only compound HIV-1 protease inhibitor and they do major clinical trials have demonstrated the clinical efficacy of lopinavir/ritonavir in both patients with antiretroviral-naïve and in-knowledge. The immunologic and virologic benefits of treatment with this agent have been proven in adults with HIV, adolescents, and children. Little research supports the use of lopinavir/ritonavir monotherapy as a treatment for some patients. The drug is characterized by a large genetic resistance and appears to be more tolerant of adherence than previous, undeveloped PIs.
In 2020 Cipla NSE 0.45% has received approval from the US healthcare provider USFDA for Lopinavir and oral Ritonavir tablets used to treat AIDS in infants and toddlers. Its Approval by US Food and Drug Administration (USFDA) for a new formulation to take Lopinavir / Ritonavir 40mg / 10 mg oral pellets to Cipla. Such approvals are expected to drive the market growth.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Lopinavir/Ritonavir Market at: https://orionmarketreports.com/request-sample/?id=92649&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– AbbVie Inc., Merck & Co., Inc., GlaxoSmithKline plc, Sanofi SA, and Pfizer Inc., and Cipla Inc. among others.
A full report Lopinavir/Ritonavir Market of is available at: https://orionmarketreports.com/lopinavir-ritonavir-market/92649/
Global Lopinavir/Ritonavir Market Report by Segment
By Type
- Antiretroviral
- Protease Inhibitor (Anti-HIV)
By Application
- Adult
- Children
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
